CorVista System with PH Add-On vs Tempus ECG-AF

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by CorVista Health
VS
by Tempus AI, Inc.

AI Verdict

Tool A focuses on the rapid, non-invasive diagnosis of coronary artery disease and pulmonary hypertension using a broad range of cardiac and hemodynamic signals. In contrast, Tool B specializes in predicting the risk of new-onset atrial fibrillation in patients aged 65 or older by analyzing 12-lead ECG recordings. While both are FDA-cleared AI tools in cardiology, their distinct diagnostic targets and methodologies make them suitable for different clinical needs.

Choose CorVista System with PH Add-On if…

Choose the CorVista System with PH Add-On if you require a rapid, non-invasive, point-of-care diagnostic solution for the immediate assessment of coronary artery disease and pulmonary hypertension. This tool is ideal for situations where avoiding radiation, contrast agents, or exercise is crucial, and quick results are needed to inform urgent clinical decisions.

View CorVista System with PH Add-On →

Choose Tempus ECG-AF if…

Choose Tempus ECG-AF if your goal is to proactively identify patients aged 65 or older who are at increased risk of developing new-onset atrial fibrillation within the next 12 months. This AI-based algorithm integrates seamlessly with existing 12-lead ECG workflows to support early identification and enable timely follow-up for preventative management.

View Tempus ECG-AF →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature CorVista System with PH Add-On Tempus ECG-AF
Pricing Unknown Contact vendor
Deployment Cloud-based, point-of-care system. Software solution, integrated into healthcare facility systems with advanced cardiology algorithms.
BAA Available Unknown Yes AI-estimated
FDA Status Cleared AI-estimated Yes AI-estimated
HIPAA Unknown Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

CorVista System with PH Add-On

Tool A, the CorVista System, emphasizes a non-invasive, point-of-care approach that requires no radiation, contrast agents, injections, fasting, or exercise, with rapid results available within minutes via a secure web portal. This significantly enhances the patient experience and streamlines the diagnostic workflow for clinicians.

Clinical Value

CorVista System with PH Add-On

Both tools are FDA-cleared, demonstrating clinical utility. However, Tool A provides a rapid, non-invasive diagnostic assessment for *existing* coronary artery disease and pulmonary hypertension, addressing immediate clinical needs for symptomatic patients. Tool B offers a valuable *predictive* risk assessment for future atrial fibrillation, but Tool A's broader and more direct diagnostic capability for two major conditions provides more immediate clinical impact.

Pricing & Value

Tempus ECG-AF

Tool B, Tempus ECG-AF, explicitly details CMS reimbursement availability with specific CPT codes and a Medicare rate, offering a clear and tangible financial value proposition for healthcare providers. In contrast, Tool A's pricing information is only available upon contact, lacking transparency regarding its economic value.

Enterprise Readiness

Tempus ECG-AF

Tool B explicitly states 'yes' for both HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are critical assurances for healthcare organizations adopting new technologies. While Tool A is 'likely' compliant, the definitive statements from Tempus provide greater confidence for enterprise integration and data handling.

Innovation

CorVista System with PH Add-On

Tool A introduces a highly innovative, non-invasive, point-of-care diagnostic platform that analyzes cardiac and hemodynamic signals without the need for traditional, often burdensome, diagnostic procedures like radiation or injections. This represents a more significant paradigm shift in diagnostic methodology compared to Tool B, which applies AI to existing 12-lead ECG data for predictive risk assessment.

Support & Docs

Tempus ECG-AF

Tempus (Tool B) provides clear and accessible customer support channels, including phone, email, and live chat, with specified business hours and response times, and also mentions a document library. For CorVista System (Tool A), specific public information regarding customer support contacts or comprehensive documentation portals was not readily available through web searches.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature CorVista System with PH Add-On Tempus ECG-AF
Tool Name CorVista System with PH Add-On Tempus ECG-AF
Company Analytics for Life Tempus AI, Inc.
Primary Diagnostic/Identification Focus Rapid assessment of coronary artery disease and pulmonary hypertension. Identifies patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.
Input Data Type Cardiac and hemodynamic signals (non-invasive, no radiation, contrast agents, injections, fasting, or exercise required). 12-lead ECG recordings.
Target Patient Population/Conditions Patients requiring assessment for coronary artery disease and pulmonary hypertension. Patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery.
Reimbursement Information Not specified CMS reimbursement available (CPT 0764T and CPT 0765T to APC 5734, Medicare rate of $128.90, effective January 1, 2025).

Videos

Demos, reviews, and walkthroughs featuring CorVista System with PH Add-On and Tempus ECG-AF.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

The CorVista System with PH Add-On is designed for the rapid, non-invasive assessment of coronary artery disease (CAD) and pulmonary hypertension (PH) using machine-learned algorithms. Tempus ECG-AF, on the other hand, is an AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months.
The CorVista System with PH Add-On is intended for symptomatic patients with cardiovascular symptoms and risk factors, and it offers a non-invasive, point-of-care test. Tempus ECG-AF is specifically for patients aged 65 or older who do not have a known history of AF, pacemakers, ICDs, or recent cardiac surgery.
The CorVista System with PH Add-On analyzes cardiac and hemodynamic signals collected at the point-of-care. Tempus ECG-AF analyzes 12-lead ECG recordings and is compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems.
For the CorVista System with PH Add-On, pricing information requires contacting the vendor, and no specific reimbursement details are provided. For Tempus ECG-AF, CMS reimbursement is available with CPT codes 0764T and 0765T, assigned to APC 5734, with a Medicare rate of $128.90, effective January 1, 2025.
The CorVista System with PH Add-On is non-invasive and requires no radiation, contrast agents, injections, fasting, or exercise, providing rapid results within minutes. Tempus ECG-AF utilizes standard 12-lead ECG recordings, which are a routine and non-invasive procedure, and its results are interpreted in conjunction with other diagnostic information and clinical history.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.